Bispecific Antibody CDX-527 Enters Phase 1 Trial in Solid Tumors
September 16th 2020The bispecific antibody CDX-527 is now under investigation in patients with advanced or metastatic solid tumors who have progressed during or following standard-of-care treatment with the recent initiation of a open-label phase 1 trial.
ALKS 4230 Under Exploration for Advanced Malignant Solid Tumors in ARTISTRY-3 Trial
September 15th 2020Investigators are evaluating the clinical and immunological impact of the experimental, engineered fusion protein ALKS 4230 on the tumor microenvironment of several advanced, malignant solid tumors in the recently initiated phase 2 ARTISTRY-3 trial.